Komori
ASKA Pharmaceutical Holdings (4886) · InitiativeFirst stated

Exclusive development and sales rights in Japan for MHB018A, a treatment for thyroid eye disease, from Minghui Pharmaceutical

First written in FY2027-H1. . Latest entry: FY2027-H1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
In-licensing of Exclusive Development and Commercialization Rights in Japan for MHB018AA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2027-H1First statedAnnual report

    「The company's subsidiary, あすか製薬株式会社, signed a license agreement with Minghui Pharmaceutical (Hangzhou) Limited for the in-licensing of MHB018A, a treatment for thyroid eye disease. Effective date of the agreement: 4 November 2026. Grant of exclusive development and sales rights for MHB018A in Japan」

    On 4 November 2026, after the end of the interim period, the company signed an agreement to in-license from Minghui Pharmaceutical the exclusive development and sales rights in Japan for MHB018A, a treatment for thyroid eye disease. The agreement includes an upfront payment, development and sales milestones, and royalties.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Exclusive development and sales rights in Japan for MHB018A, a treatment for thyroid eye disease, from Minghui Pharmaceutical | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) | Komori